Inactive Instrument
Norda ASA Share Price Oslo Bors
Stocks
NORD
NO0010285190
Biotechnology & Medical Research
| Market Cap | 513M 55.23M 47.29M 44.2M 40.45M 75.85M 5.28B 77.13M 522M 204M 2.65B 207M 203M 8.73B | P/E 2023 * |
-
| P/E 2024 | 3.26x |
|---|---|---|---|---|---|
| Enterprise Value | 264M 28.45M 24.36M 22.77M 20.84M 39.07M 2.72B 39.73M 269M 105M 1.37B 107M 104M 4.5B | EV / Sales 2023 |
-1.24x | EV / Sales 2024 | 0.4x |
| Free-Float |
6.26% | Yield 2023 * |
-
| Yield 2024 | 32.5% |
| 04-09 | Exercise of Warrants by primary insiders | AQ |
| 10/07/25 | Mandatory Notification of Trade | AQ |
| 04/06/25 | Ocean Sun: Mandatory notification of trade | AQ |
| 27/03/25 | Nykode Therapeutics - Mandatory Notification of Trade by Closely Associated Party of a Primary Insider | AQ |
| 03/03/25 | Notification of trade | AQ |
| 1 day | +3.37% |
| Manager | Title | Age | Since |
|---|---|---|---|
Frode Westvold
CEO | Chief Executive Officer | - | 07/04/2013 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 54 | 30/01/2014 | |
| Director/Board Member | 68 | 19/06/2013 | |
| Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.37% | -6.12% | - | - | 47.66M | ||
| -0.74% | +4.48% | +3.74% | +22.46% | 51.61B | ||
| +1.01% | +3.86% | +471.68% | +577.49% | 44.89B | ||
| +0.16% | +9.96% | +36.14% | +20.40% | 42.77B | ||
| -0.66% | +7.05% | +18.59% | +83.42% | 42.58B | ||
| +0.88% | -3.48% | +17.20% | +57.20% | 31.82B | ||
| -0.12% | +7.18% | +33.73% | +148.24% | 17.33B | ||
| -0.53% | +1.39% | - | - | 16.63B | ||
| +0.58% | +4.00% | +7.17% | +30.59% | 14.76B | ||
| +1.15% | +6.62% | +84.49% | +47.81% | 14.09B | ||
| Average | +0.51% | +4.83% | +84.09% | +123.45% | 30.72B | |
| Weighted average by Cap. | +0.10% | +5.13% | +100.58% | +142.48% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 86.92M 9.35M 8.01M 7.49M 6.85M 12.85M 895M 13.06M 88.49M 34.48M 449M 35.1M 34.34M 1.48B | 372M 40.02M 34.26M 32.03M 29.31M 54.96M 3.83B 55.89M 379M 147M 1.92B 150M 147M 6.33B |
| Net income | 31.17M 3.35M 2.87M 2.68M 2.46M 4.61M 321M 4.69M 31.74M 12.36M 161M 12.59M 12.32M 530M | 126M 13.55M 11.61M 10.85M 9.93M 18.62M 1.3B 18.93M 128M 49.95M 651M 50.86M 49.76M 2.14B |
| Net Debt | -311M -33.5M -28.68M -26.81M -24.53M -46M -3.21B -46.78M -317M -123M -1.61B -126M -123M -5.3B | -249M -26.78M -22.93M -21.43M -19.61M -36.78M -2.56B -37.4M -253M -98.69M -1.29B -100M -98.3M -4.23B |
Employees
-
















